ShiraTronics Secures Significant Funding
ShiraTronics, a clinical-stage medical device company, has successfully closed a $66 million Series B financing round. This funding will empower them to advance their groundbreaking treatment aimed at alleviating the burdens of chronic migraine for countless patients.
New Investment Leads
The financing round was spearheaded by Norwest Venture Partners, bringing in a mix of both new and returning investors. Other investors participating in this vital funding include Seroba, OSF Ventures, and the Global BioAccess Fund. This influx of capital was crucial for ShiraTronics as they set their sights on expanding their innovative neuromodulation therapies.
Promising Treatment Approaches
ShiraTronics specializes in developing neurostimulation therapies tailored for chronic migraine patients. Their recent pilot studies have showcased early promise in improving the quality of life for individuals who, until now, have faced limited effective treatment options. The company’s Migraine Therapy System is designed to manage migraine symptoms, offering a beacon of hope in a field plagued with treatment-resistant cases.
Focus on Clinical Trials
Launching a Pivotal Trial
This funding is set to support ShiraTronics' recent FDA-approved pivotal trial named RELIEV-CM2, a randomized, sham-controlled clinical study designed to assess the safety and effectiveness of their device. Many currently suffer from chronic migraines that are unresponsive to conventional treatments, and ShiraTronics is committed to changing that narrative.
Hearing from Leadership
The CEO of ShiraTronics, Rob Binney, emphasized the enormity of the challenge chronic migraines pose, with roughly 3 million patients in the U.S. experiencing debilitating attacks. Binney is optimistic about the continuing development and efficacy of their therapy system, stating their focused intention to bring meaningful relief to patients.
The Need for Advanced Treatments
Chronic migraine affects about 5 to 6 million people in the U.S., with around 3 million encountering significant resistance to existing therapies. Traditional methods often fall short, leading many to cope with their pain in silence. Recent studies indicate that more than 50% of chronic migraine patients express dissatisfaction with their current treatment plans due to minimal improvement in symptoms.
Exploring Neuromodulation Systems
Innovative Device Design
ShiraTronics has developed a unique, drug-free neuromodulation system that aims to address chronic migraine symptoms. This minimally invasive device is implanted beneath the skin in the head area, delivering targeted electrical pulses to manage and potentially alleviate pain signals responsible for migraines.
Promoting Patient Empowerment
The system also allows patients to regulate their therapy through a dedicated application, fostering a sense of control over their chronic condition. This device not only aims to interrupt the painful signals but also proactively prevents migraine symptoms from occurring.
Future Outlook for ShiraTronics
Having received Breakthrough Device designation from the FDA in 2021, ShiraTronics is positioned well within the medical device domain. The positive outcomes from their pilot studies indicate a promising path forward in seeking further FDA approvals and gearing up for a commercial launch. With intentions to expand their reach and improve the quality of life for those suffering from chronic migraines, ShiraTronics is on the frontier of a potential healthcare revolution.
About ShiraTronics
ShiraTronics stands at the forefront of innovation in medical devices, specifically focusing on neurostimulation solutions for chronic migraine sufferers. With a commitment to improving patient outcomes and reducing headache incidences, ShiraTronics aims to transform how chronic migraine is treated and managed.
Frequently Asked Questions
What is the purpose of ShiraTronics fundraising?
The recent $66 million funding aims to support clinical trials and the commercial launch of their innovative migraine therapy.
How does the ShiraTronics device work?
The ShiraTronics device delivers targeted electrical pulses to the nerves associated with migraine pain, helping to alleviate symptoms.
Who are the investors in ShiraTronics?
Investors include Norwest Venture Partners, U.S. Venture Partners, Amzak Health, and others, contributing to the development of groundbreaking migraine treatment.
What is the RELIEV-CM2 trial?
RELIEV-CM2 is a pivotal clinical trial to evaluate the safety and effectiveness of ShiraTronics' Migraine Therapy System for chronic migraine patients.
Why is chronic migraine a concern for patients?
Chronic migraine significantly impairs quality of life and current treatments often fail to provide effective relief for many sufferers, leading to an urgent need for better solutions.
